Merck KGAA is teaming up with Xiamen, China-based Amoy Diagnostics Co. Ltd. to develop and commercialize a new liquid-biopsy RAS biomarker for metastatic colorectal cancer based on Amoy’s ADx-SuperARMS real-time polymerase chain reaction technology.
The companies expect to launch the new assay in China in 2017, and then expand it to Argentina, India, Mexico,...